Inotuzumab-Ozogamicin induces remissions and enables allogeneic SCT in patients with Blinatumomab-refractory B-precursor acute lymphoblastic leukemia

被引：0
|
作者：
Buecklein, Veit [1 ,2 ]
Fraccaroli, Alessia [1 ]
Prevalsek, Dusan [1 ]
Haebe, Sarah [1 ]
Schulz, Christoph [1 ]
Zoellner, Anna-Katharina [1 ]
Spiekermann, Karsten [1 ]
Subklewe, Marion [1 ,2 ]
Tischer, Johanna [1 ]
机构：
[1] Univ Munich, Univ Hosp, Dept Med 3, Munich, Germany
[2] Univ Munich, Gene Ctr, Translat Canc Immunol, Munich, Germany
来源：
BONE MARROW TRANSPLANTATION | 2018年 / 53卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P033
引用
收藏
页码：170 / 171
页数：2
相关论文
共 50 条
  • [21] Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ueda, Tomoaki
    Fukushima, Kentaro
    Kusakabe, Shinsuke
    Yoshida, Koki
    Suga, Makiko
    Nakai, Ritsuko
    Koike, Midori
    Hino, Akihisa
    Akuta, Keigo
    Toda, Jun
    Nagate, Yasuhiro
    Doi, Yukiko
    Fujita, Jiro
    Yokota, Takafumi
    Hosen, Naoki
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [22] Primary refractory B-cell lymphoblastic leukemia with extramedullary disease - a distinctive response to blinatumomab and inotuzumab ozogamicin
    Silva, Wellington Fernandes da
    Marquez, Gabriel Lacerda
    Salim, Rafael Calil
    Rocha, Vanderson
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2019, 41 (04) : 356 - 359
  • [23] Characteristics of Medicare patients with relapsed/refractory acute lymphoblastic leukemia initiating treatment with inotuzumab ozogamicin, blinatumomab, or other agents.
    Russell-Smith, T. Alexander
    Shah, Richa
    Silverstein, Alison R.
    Petrilla, Allison A.
    Leinwand, Brian
    Norris, Diane
    Schroeder, Amy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19009 - E19009
  • [24] BLINATUMOMAB SAFETY AND ACTIVITY IN OLDER PATIENTS WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN TWO PHASE 2 STUDIES
    Kantarjian, H.
    Stein, A.
    Bargou, R.
    Grande, C.
    Larson, R.
    Stelljes, M.
    Benjamin, J.
    Jia, C.
    Topp, M.
    HAEMATOLOGICA, 2015, 100 : 8 - 8
  • [25] Blinatumomab or Inotuzumab Ozogamicin As Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
    Unal, Ali
    BLOOD, 2022, 140 : 12798 - 12798
  • [26] Inotuzumab Ozogamicin in Indian Patients with B-Cell Acute Lymphoblastic Leukemia
    Borah, Pronamee
    Mohan, Vivek
    Jain, Sachin
    Capoor, Varun
    Naithani, Rahul
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024,
  • [27] Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
    Stelmach, Patrick
    Wethmar, Klaus
    Groth, Christoph
    Wenge, Daniela V.
    Albring, Joern
    Mikesch, Jan-Henrik
    Schliemann, Christoph
    Reicherts, Christian
    Berdel, Wolfgang E.
    Lenz, Georg
    Stelljes, Matthias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (10): : E724 - E733
  • [28] Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Deangelo, Daniel J.
    Chen, Ying
    Cassaday, Ryan D.
    Hibma, Jennifer
    Yang, Derek Z.
    Garrett, May
    Zhang, Fan
    Dimitrov, Svetoslav H.
    Vandendries, Erik
    Kantarjian, Hagop M.
    BLOOD, 2024, 144 : 732 - 733
  • [29] Outcome of Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients with Extramedullary Disease Receiving Inotuzumab Ozogamicin
    Kayser, Sabine
    Sartor, Chiara
    Panitz, Nydia
    Fante, Matthias
    Lutz, Christoph
    Wolff, Daniel
    Ho, Anthony
    Papayannidis, Cristina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S265 - S265
  • [30] Mini-hyper CVD plus CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia
    McCall, David
    Jabbour, Elias
    Roth, Michael
    Nunez, Cesar
    Cuglievan, Branko
    PEDIATRIC BLOOD & CANCER, 2023, 70 (01)
12345